Progressive supranuclear palsy (PSP) is a rare and progressive neurodegenerative disorder.
PSP can affect eye movements, walking, balance, speech, swallowing, mood, behaviour and thought processes (cognition).
Although there’s currently no cure for PSP, a range of drugs, treatments and therapies are available to manage the symptoms.
The management of PSP is focused on optimizing quality of life, relieving symptoms and assisting patients with their activities of daily living (ADL).
PSP symptoms most commonly occur in the person’s 60s, with slightly more men than women affected. The minimum age of onset for diagnostic purposes is currently set at 40.
PSP affects differing parts of the brain, including the brain stem, the basal ganglia and outer part of the brain – the cerebral cortex.
Some of the PSP symptoms are similar to those of Parkinson’s disease (PD), especially in the early stages of PSP.
PSP differs to PD in that it progresses faster and the symptoms are more severe.